STOCK TITAN

SION insider files Form 144 for 25,000-share sale via Morgan Stanley

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Sionna Therapeutics (SION) reported a Form 144 notice showing a proposed sale of 25,000 common shares—about 0.057% of the 44,139,823 shares outstanding—via Morgan Stanley Smith Barney on 08/20/2025 on NASDAQ. The filer acquired the shares on 08/20/2025 by exercising stock options and paid cash for them. The aggregate market value of the proposed sale is listed as $537,000.00. The filing notes there were no reported sales in the prior three months. The filer certifies they are not aware of any undisclosed material adverse information and includes the standard Rule 144 and Rule 10b5-1 representations.

Positive

  • Timely disclosure of proposed sale under Rule 144 demonstrates compliance with SEC reporting requirements
  • Transaction funded in cash via option exercise, indicating the sale stems from exercised equity rather than other transfers
  • No reported sales in prior three months for the account, suggesting this is not part of a recent pattern of selling

Negative

  • Insider sale is disclosed, which some investors may view negatively despite its small size relative to outstanding shares

Insights

TL;DR: Routine insider option exercise followed by a small sale; immaterial to market capitalization.

The filing documents a contemporaneous exercise of stock options and a proposed sale of 25,000 shares valued at $537,000, representing roughly 0.06% of outstanding shares. This is a standard disclosure under Rule 144 and does not indicate prior open-market selling activity for this account in the past three months. From a market-impact perspective, the size is small relative to the company’s outstanding shares so near-term price impact is likely limited.

TL;DR: Compliance-focused filing showing timely disclosure of insider exercise and planned sale; governance process appears followed.

The notice shows the filer exercised options and intends to sell the resulting shares through Morgan Stanley Smith Barney, with cash payment at acquisition. The form includes the required certification about absence of undisclosed material information and mentions Rule 10b5-1 considerations. This is consistent with standard insider reporting practices and indicates procedural adherence to disclosure rules.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Form 144 filed by SION mean?

Form 144 notifies the market of a proposed sale of restricted or control securities; here it shows a proposed sale of 25,000 SION shares.

When is the SION sale expected to occur?

The filing lists the approximate date of sale as 08/20/2025 on NASDAQ through Morgan Stanley Smith Barney.

How were the 25,000 shares acquired?

The shares were acquired on 08/20/2025 by an exercise of stock options and payment was made in cash.

How large is the proposed sale relative to Sionna's shares outstanding?

The 25,000 shares represent about 0.057% of the 44,139,823 shares outstanding reported in the filing.

What is the aggregate market value of the proposed sale?

The filing lists an aggregate market value of $537,000.00 for the 25,000 shares.
Sionna Therapeutics

NASDAQ:SION

SION Rankings

SION Latest News

SION Latest SEC Filings

SION Stock Data

1.61B
30.22M
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM